

A *let-7* microRNA-binding site polymorphism in 3'-untranslated region of *KRAS* gene predicts response in wild-type *KRAS* patients with metastatic colorectal cancer treated with cetuximab monotherapy

W. Zhang^{1†}, T. Winder^{1†}, Y. Ning¹, A. Pohl¹, D. Yang², M. Kahn¹, G. Lurje³, M. J. LaBonte⁴, P. M. Wilson⁴, M. A Gordon¹, S. Hu-Lieskovan¹, D. J. Mauro⁵, C. Langer⁶, E. K. Rowinsky⁷ & H.-J. Lenz^{1,2*}

¹Division of Medical Oncology; ²Department of Preventive Medicine, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA; ³Department of Visceral- and Transplantation Surgery, University Hospital Zurich, Zurich, Switzerland; ⁴Department of Pathology, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA; ⁵Oncology, Merck & Co., Inc., NJ; ⁶Early Oncology, Bristol-Myers Squibb Pharmaceuticals Limited, New York; ⁷Oncology, ImClone Systems, New York, NY, USA

Received 9 March 2010; revised 13 April 2010; accepted 16 April 2010

Purpose: Recent studies have found that *KRAS* mutations predict resistance to monoclonal antibodies targeting the epidermal growth factor receptor in metastatic colorectal cancer (mCRC). A polymorphism in a *let-7* microRNA complementary site (lcs6) in the *KRAS* 3' untranslated region (UTR) is associated with an increased cancer risk in non-small-cell lung cancer and reduced overall survival (OS) in oral cancers. We tested the hypothesis whether this polymorphism may be associated with clinical outcome in *KRAS* wild-type (*KRAS*_{wt}) mCRC patients treated with cetuximab monotherapy.

Patients and methods: The presence of *KRAS let-7 lcs6* polymorphism was evaluated in 130 mCRC patients who were enrolled in a phase II study of cetuximab monotherapy (IMCL-0144). Genomic DNA was extracted from dissected formalin-fixed paraffin-embedded tumor tissue, *KRAS* mutation status and polymorphism were assessed using direct sequencing and PCR restriction fragment length polymorphism technique.

Results: *KRAS let-7 lcs6* polymorphism was found to be related to object response rate (ORR) in mCRC patients whose tumors had *KRAS*_{wt}. The 12 *KRAS*_{wt} patients harboring at least a variant G allele (TG or GG) had a 42% ORR compared with a 9% ORR in 55 *KRAS*_{wt} patients with *let-7 lcs6* TT genotype ($P = 0.02$, Fisher's exact test). *KRAS*_{wt} patients with TG/GG genotypes had trend of longer median progression-free survival (3.9 versus 1.3 months) and OS (10.7 versus 6.4 months) compared to those with TT genotypes.

Conclusions: These results are the first to indicate that the *KRAS* 3'UTR polymorphism may predict for cetuximab responsiveness in *KRAS*_{wt} mCRC patients, which warrants validation in other clinical trials.

Key words: cetuximab, *KRAS*, microRNA polymorphism, metastatic colon cancer

Introduction

Colorectal cancer (CRC) remains the second leading cause of cancer deaths in the United States. In 2009, an estimated 146 970 new cases will be diagnosed and 49 920 people will die from this disease [1]. Cetuximab, an immunoglobulin G1 monoclonal antibody to the epidermal growth factor receptor (EGFR), has demonstrated clinical efficacy as monotherapy and

when combined with chemotherapy in the treatment of advanced disease [2–7].

Recently, *KRAS* mutation status has been demonstrated to be a predictive marker of clinical benefit to monoclonal antibodies targeting EGFR [8–11]. Although *KRAS* mutations, particularly those involving codons 12 and 13 that are found in approximately 30%–40% of patients with metastatic colorectal cancer (mCRC), strongly relate to resistance to monoclonal antibodies targeting EGFR, not all mCRC patients with *KRAS*_{wt} derive benefit from these agents, and there is a need to identify molecular markers that better identify which *KRAS*_{wt} mCRC patients benefit from treatment. Previous studies had identified additional markers in *KRAS*_{wt} patients that can better predict for cetuximab responsiveness. For example, Jacobs et al. found that

*Correspondence to: Dr Heinz-Josef Lenz, Sharon A. Carpenter Laboratory, Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA. Tel: +1-323-865-3967; Fax: +1-323-865-0061; E-mail: lenz@usc.edu

†These two authors contributed equally.

gene expression levels of two EGFR ligands, epiregulin and amphiregulin (AREG) related to favorable outcome in 220 chemorefractory *KRAS*^{wt} mCRC patients treated with cetuximab and irinotecan [12]. Several studies have demonstrated that high EGFR gene copy number could be a predictive marker in CRC patients treated with cetuximab [13, 14]. Furthermore, Laurent-Puig et al. showed that *BRAF* status, cytoplasmic expression of *PTEN* and EGFR amplification were associated with clinical outcome in *KRAS*^{wt} patients treated with a cetuximab-based regimen [15]. Finally, Sartore-Bianchi et al. pointed out that *PI3KCA* mutations in CRC were associated with clinical resistance to EGFR-targeted monoclonal antibodies including cetuximab and panitumumab [16].

In addition to tumor characteristics playing an important role in determining responsiveness to cetuximab, the genetic makeup of patients may also contribute to determining cetuximab sensitivity. Several studies have found that FcγRIIa–FcγRIIIa polymorphisms, as well as COX-2 and EGFR germline polymorphisms, are associated with clinical outcome in mCRC patients treated with single-agent cetuximab independent of *KRAS* status [17–19]. MicroRNAs are small, noncoding RNAs that regulate gene expression by degrading and/or suppressing the translation of target messenger RNA (mRNA) by base pairing in the 3′-untranslated region (UTR) of mRNA [20]. Very recently, microRNA polymorphisms were discovered and are becoming increasingly important in the fast growing field of personalized medicine. MicroRNA polymorphisms could be present at or near a microRNA-binding site of functional genes. MicroRNA polymorphisms can affect gene expression by interfering with microRNA function. They have been shown to affect drug response and have the potential to confer drug resistance [21, 22]. The *let-7* family of microRNAs were found to regulate *KRAS* activity by binding to the 3′-UTR of human *KRAS* gene [23]. Previous study demonstrated that a microRNA polymorphism in the *let-7* microRNA complementary-binding site (*lcs6*) of the 3′UTR of *KRAS* gene was associated with increased *KRAS* expression in *in vitro* model [24]. Furthermore, this polymorphism was found to be associated with increased cancer risk in non-small-cell lung cancer (NSCLC) patients and reduced overall survival (OS) in oral cancers [24, 25], suggesting functional and clinical significance.

Due to the important role of *KRAS* mutation status in predicting cetuximab efficacy in CRC, we hypothesized that this *KRAS let-7 lcs6* polymorphism may predict efficacy of cetuximab in *KRAS*^{wt} mCRC patients. We studied this polymorphism in 130 mCRC patients who were refractory to fluoropyrimidine, irinotecan, and oxaliplatin, and treated with cetuximab as monotherapy in a phase II study (IMCL-0144).

patients and methods

patient characteristics and statistical analysis

One hundred and thirty (38%) of the 346 patients enrolled in IMCL-0144 had tumor tissues available and amenable for analysis of *KRAS let-7 lcs6* polymorphism (Table 1). IMCL-0144 involved patients with histopathologically confirmed mCRC, who were treated with cetuximab monotherapy following failure of therapeutic regimens that included fluoropyrimidine, irinotecan and oxaliplatin [26]. All 130 patients who had available tumor tissue samples were included in the present

Table 1. Pretreatment characteristics among patients whose specimens available for genotyping in IMCL-0144

	Single-agent cetuximab (n = 130)	
	Frequency	%
Median age, year (range)	60 (29–85)	
Sex		
Female	66	51
Male	64	49
Race		
Caucasian	121	93
African-American	3	2
Asian	3	2
Other	3	2
ECOG performance status		
0	52	41
1	76	59
2	0	0
<i>KRAS</i> mutation status* (*Codons 12 and 13)		
Wild-type	88	68
Mutant	42	32

ECOG, Eastern Cooperative Oncology Group.

pharmacogenetic study, irrespective of clinical outcome and *KRAS* mutation status. This study was performed at the University of Southern California/Norris Comprehensive Cancer Center (USC/NCCC) following approval by the Institutional Review Board of the University of Southern California for Medical Sciences. All patients provided their written informed consent for tissue collection to allow study of molecular correlates.

The primary objective of this pharmacogenetic study was to evaluate relationships between *KRAS let-7 lcs6* polymorphism and tumor response in *KRAS*^{wt} mCRC patients treated with single-agent cetuximab, whereas secondary objectives included evaluations of relationships of the polymorphism to progression-free survival (PFS) and OS. The PFS was calculated from the time of the first date of cetuximab treatment until the first observation of disease progression or death from any cause. If a patient had not progressed or died, PFS was censored at the time of the last follow-up. The OS time was calculated as the period from the first day of cetuximab infusion or until death from any cause, at which the point data were censored.

The association of *KRAS let-7 lcs6* polymorphism with tumor response was determined by contingency table and the Fisher's exact test. The association between this polymorphism with OS and PFS was analyzed using Kaplan–Meier plots and the log-rank test. The level of significance was set to a *P* value of <0.05, and *P* values are given for -two-sided testing. All statistical tests were performed using the SAS statistical package version 9.1 (SAS Institute Inc. Cary, NC), and Epilog Plus Version 1.0 (Epicentre Software, Pasadena, CA).

clinical evaluation of response criteria

Objective tumor response was assessed every 6 weeks during the course of the study and criteria were based on modified World Health Organisation guidelines [26]. Response to cetuximab was determined by an independent response assessment committee that was blinded to the investigator-reported measurements and assessments were reported in the study. A partial response required at least a 50% reduction in the sum of the bidimensional products of all measurable lesions documented at least 4 weeks apart. Treatment was continued in the absence of intolerable toxicity

or progressive disease, defined as at least a 25% increase in measurable disease, unequivocal growth of existing nonmeasurable disease, the appearance of one or more new lesions or reappearance of old lesions.

KRAS mutation status and KRAS *let-7 lcs6* genotyping

Tissue specimens from primary tumors were collected and genomic DNA was extracted using the QIAamp kit (Qiagen, CA). *KRAS* mutation status was determined by direct sequencing as previously described [17]. Briefly, microdissected tumor DNA was amplified using following primer set: forward: 5'-TGA CTG AAT ATA AAC TTG TGG TAG TTG -3', and reverse: 5'-TCG TCC ACA AAA TGA TTC TGA A-3'. PCR fragments were sequenced on an ABI 3100A Capillary Genetic Analyzer (Applied Biosystems), and analyzed in both sense and antisense directions for the presence of heterozygous mutations. Analysis of the DNA sequence was performed using ABI Sequencing Scanner v1.0 (Applied Biosystems). *KRAS let-7 lcs6* polymorphism (rs61764370) was tested using PCR restriction fragment length polymorphism (PCR-RFLP) technique. Briefly, forward primer 5'-TTA GGA GAG ACG GGG TTT CA-3' and reverse primer 5'-AAA TGA GTT CTG CAA AAC AGG-3' were used for PCR amplification, PCR products were digested by restriction enzyme *TfiI* (New England Biolab, MA), and alleles were separated on 4% NuSieve ethidium bromide-stained agarose gel.

results

The 130 patients whose tissues samples were available for pharmacogenomic and molecular analyses in the present study had a similar median PFS (1.3 months), OS (6.3 months), and ORR (9.2%) values compared with patients whose tissues samples were not available for assessment in the present study ($n = 216$); the respective median values were PFS 1.5 months, OS 6.8 months, and ORR 13%, respectively [26].

Analysis of *KRAS let-7 lcs6* polymorphism was available in 111 patients due to exhaustion of available DNA from previous diagnostic testing. Thirteen of 111 patients (12%) were not assessable for tumor response. In 98 patients assessable for tumor response, 67 patients had wild-type *KRAS* and 31 patients had mutant *KRAS*. None of the 31 patients with a documented *KRAS* mutation responded to cetuximab, whereas 10 of the 67 *KRASwt* patients responded (0% versus 15%, respectively; $P = 0.01$, Fisher's exact test). In the 111 patients assessable for PFS and OS, *KRASwt* patients had

significantly longer PFS ($P = 0.023$) and OS ($P = 0.02$) values compared with *KRAS*-mutated patients. Fifty-five (82%) of the 67 *KRASwt* patients had the *KRAS let-7 lcs6* TT genotype. There are 12 *KRASwt* patients harboring at least one *let-7 lcs6* variant G allele (TG or GG). These 12 patients had a 42% (5/12) ORR compared with 55 *KRASwt* patients with wild-type TT genotype who had a 9% (5/55) ORR ($P = 0.02$, Fisher's exact test; Figure 1). None of the 31 *KRAS* mutant patients had an objective response to cetuximab regardless of *KRAS let-7 lcs6* polymorphism. Of the 28 *KRAS* mutant patients with *KRAS let-7 lcs6* TT genotype, 10 had stable disease and 18 had progressive disease as their best response, whereas all 3 patients whose tumors had *KRAS* mutations and had a heterozygous TG genotype had progressive disease as their best response. There were no statistically significant associations between *KRAS let-7 lcs6* polymorphism and OS, PFS either in wild-type or in mutant *KRAS* patients (Table 2). *KRASwt* patients who possessed a TT genotype ($n = 62$) had a median PFS of 1.3 months (95%CI: 1.2–1.5 months) compared with patients with at least one variant allele (TG or GG; $n = 13$) who had a median PFS of 3.9 months (95% CI: 1.2–5.5 months; $P = 0.25$, log-rank test). The median OS for *KRASwt* patients with a TT genotype was 6.4 months (95%CI: 3.6–8.2 months) compared with 10.7 months (95% CI: 5.5–12.7 months) for those harboring at least one variant allele ($P = 0.33$, log-rank test; Figures 2 and 3).

discussion

Our data have shown for the first time that a *KRAS let-7* microRNA-binding site polymorphism (*lcs6*) in the 3'-UTR of the *KRAS* gene relates to tumor response in *KRASwt* mCRC patients treated with cetuximab monotherapy. Although patient numbers are small, our preliminary data demonstrated that *KRASwt* patients with *KRAS let-7 lcs6* TT genotype had worse ORR compared with those with TG/GG genotype. The 12 *KRASwt* patients harboring at least a variant G allele (TG or GG) had a 42% ORR compared with 55 *KRASwt* patients who possessed wild-type TT genotype with only 9% ORR ($P = 0.02$, Fisher's exact test). Patients with TG/GG allele had a longer PFS and OS but did not reach statistical significance due to the small sample size.

MicroRNA polymorphisms are emerging as significant molecular markers in the field of personalized medicine. They have been shown to affect drug response and are reported to be associated with many diseases including cancer. *KRAS let-7 lcs6* microRNA polymorphism has been shown to be associated with oral cancer survival and lung cancer risk in different studies [24]. Christensen et al. examined the *let-7 lcs6* polymorphism and the association with disease occurrence and OS in a population-based case-control study of patients with squamous cell carcinoma of the head and neck (HNSCC). Their results suggest that HNSCC patients who carry the *KRAS let-7 lcs6* variant allele have a significantly reduced OS compared with patients with a *let-7 lcs6* wild-type TT genotype [25]. Meanwhile, Chin et al. evaluated the same *let-7 lcs6* polymorphism and its relationship with the risk of developing NSCLC. Their data have shown that the *lcs6* variant allele in a *KRAS* microRNA complementary site is significantly




Figure 1. Tumor response by *KRAS let-7 lcs6* polymorphism in *KRASwt* patients enrolled in IMCL-0144.




Figure 2. Overall survival by *KRAS let-7 lcs6* polymorphism in *KRASwt* patients treated with cetuximab monotherapy.




Figure 3. Progression-free survival by *KRAS let-7 lcs6* polymorphism in *KRASwt* patients treated with cetuximab monotherapy.

associated with increased risk for NSCLC among those with a moderate smoking history [24].

Recent studies have shown that *KRAS* is regulated by the *let-7* microRNA family. The 3'-UTR region of the human *KRAS* genes contains multiple *let-7* complementary sites (lcs), allowing *let-7* to regulate *KRAS* activity [23]. In CRC, transfection of cell lines with a *let-7a-1* precursor microRNA resulted in growth suppression and a decrease in *KRAS* protein levels, suggesting that *let-7* microRNA may play a role in suppressing colon cancer growth [27]. Moreover, it has been demonstrated that *let-7* microRNA is not only involved in the growth of colon cancer cells, but can also modulate tumor

sensitivity to chemotherapeutic agents [28]. Nakajima et al. have shown an association for members of the *let-7* family of microRNAs with responsiveness to the oral fluoropyrimidine S-1. They found the level of expression of *let-7g* strongly related to responsiveness to S-1 treatment in 46 patients with recurrent or refractory advanced CRC [28].

These findings suggest that patients with *KRASwt* CRCs who also carry a variant *KRAS let-7 lcs6* allele have a higher probability of responding to cetuximab monotherapy compared with those with wild-type TT genotype. However, these results were derived retrospectively and involve a relatively small number of patients, and therefore should be

Table 2. PFS and OS by KRAS *let-7 lcs6* polymorphism in mCRC patients treated with cetuximab monotherapy

KRAS mutation status		PFS		OS		
Polymorphism	N	KRAS wild type Median, m (95% CI)	N	KRAS mutant Median, m (95% CI)	KRAS wild type Median, m (95% CI)	KRAS mutant Median, m (95% CI)
KRAS <i>let-7 lcs6</i>						
TT	62	1.3 (1.2–1.5)	32	1.3 (1.2–2.3)	6.4 (3.6–8.2)	5.9 (2.5–7.9)
TG+GG	13	3.9 (1.5–5.5)	4	1.2 (1.2–2.8)	10.7 (5.5–12.7)	2.8 (2.3–12.4)
P value		0.25		0.71	0.33	0.84

PFS, progression-free survival; OS, overall survival; m, months; CI, confidence interval.

considered hypothesis generating and subject to confirmation in prospective and randomized controlled studies. Surprisingly, these findings that are opposite to our hypothesis that the variant *let-7 lcs6* allele has been associated with lower *let-7* levels and increased KRAS expression in NSCLC patients compared with the wild-type allele leads to greater activation of Ras/MAPK pathway, which is a known mechanism of resistance to anti-EGFR monoclonal antibodies [24]. One possible explanation for our finding is colon cancer patients whose tumors harbor the variant *lcs6* allele may also have increased KRAS expression and activity, resulting in increased tumoral oncogenic addiction in the presence of EGFR signaling. As KRAS is a key mediator of the EGFR signal transduction primarily via the MAPK pathway, it seems plausible that patients with increased tumoral KRAS expression as a result of the *lcs6* variant allele, may demonstrate increased sensitivity to the suppression of this increased oncogenic signaling by cetuximab treatment. As these tumors are *KRAS^{wt}*, cetuximab treatment will suppress EGFR tyrosine kinase phosphorylation reverting KRAS to its inactive GDP state, and the rapid loss of prosurvival signals and the simultaneous increase in proapoptotic signals may commit the cell to apoptotic death. This provides a plausible explanation as to why patients harboring the variant *KRAS let-7 lcs6* polymorphism demonstrate a superior response to cetuximab. Similar observations were found in NSCLC patients treated with the EGFR tyrosine kinase inhibitor (TKI) gefitinib [29]. Weiss et al. showed microRNA-128b negatively regulates EGFR by binding to the EGFR 3'-UTR. In their lung cancer cell line and clinical specimen analyses, they found a loss of microRNA-128b related to increased EGFR expression and responsiveness to treatment with EGFR TKIs [29]. Furthermore, *in vitro* and *in vivo* studies are needed to explore the possible mechanism between this *let-7 lcs6* polymorphism and cetuximab efficacy.

In summary, this study supports the role of *let-7 lcs6* polymorphisms as a predictive marker of cetuximab efficacy in patients with *KRAS^{wt}* mCRC treated with cetuximab as monotherapy. Due to the retrospective nature of this study, these results should be interpreted carefully. Prospective, randomized controlled and biomarker embedded clinical trials are needed to confirm and validate our findings.

funding

This work was funded by the NIH grant 5 P30CA14089-271 and the Dhont Family Foundation

acknowledgements

The study was performed in the Sharon A. Carpenter Laboratory at USC/Norris Comprehensive Cancer Center and in memory of David Donaldson. The study was previously presented at American Society of Clinical Oncology 2009 (Abstract ID 4061).

disclosure

H-JL has received honoraria from Merck KG and Bristol-Myers Squibb; EKR is employed by Imclone Systems, Inc.; DJM is employed by Merck Co., Inc; CL is employed by and has an ownership interest in Bristol-Myers Squibb.

references

- Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2009. *CA Cancer J Clin* 2009; 59: 225–249.
- Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004; 351: 337–345.
- Saltz LB, Meropol NJ, Loehrer PJ Sr. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. *J Clin Oncol* 2004; 22: 1201–1208.
- Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 2009; 27: 663–671.
- Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. *N Engl J Med* 2007; 357: 2040–2048.
- Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. *J Clin Oncol* 2008; 26: 2311–2319.
- Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009; 360: 1408–1417.
- Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. *Br J Cancer* 2007; 96: 1166–1169.
- Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. *J Clin Oncol* 2008; 26: 374–379.
- Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008; 26: 1626–1634.
- Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 2008; 359: 1757–1765.
- Jacobs B, De Roock W, Plesseaux H et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. *J Clin Oncol* 2009; 27: 5068–5074.

13. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. *Lancet Oncol* 2005; 6: 279–286.
14. Personeni N, Fieuws S, Piessevaux H et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. *Clin Cancer Res* 2008; 14: 5869–5876.
15. Laurent-Puig P, Cayre A, Manceau G et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. *J Clin Oncol* 2009; 27: 5924–5930.
16. Sartore-Bianchi A, Martini M, Molinari F et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. *Cancer Res* 2009; 69: 1851–1857.
17. Lurje G, Nagashima F, Zhang W et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. *Clin Cancer Res* 2008; 14: 7884–7895.
18. Zhang W, Gordon M, Schultheis AM et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. *J Clin Oncol* 2007; 25: 3712–3718.
19. Bibeau F, Lopez-Crapez E, Di Fiore F et al. Impact of Fc(gamma)RIIIa-Fc(gamma)RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. *J Clin Oncol* 2009; 27: 1122–1129.
20. Reddy SD, Gajula RP, Pakala SB, Kumar R. MicroRNAs and cancer therapy: the next wave or here to stay? *Cancer Biol Ther* 2010 Apr 4; 9(7). [Epub ahead of print].
21. Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. *Pharmacogenomics* 2009; 10: 399–416.
22. Sethupathy P, Collins FS. MicroRNA target site polymorphisms and human disease. *Trends Genet* 2008; 24: 489–497.
23. Johnson SM, Grosshans H, Shingara J et al. RAS is regulated by the let-7 microRNA family. *Cell* 2005; 120: 635–647.
24. Chin LJ, Ratner E, Leng S et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. *Cancer Res* 2008; 68: 8535–8540.
25. Christensen BC, Moyer BJ, Avissar M et al. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers. *Carcinogenesis* 2009; 30: 1003–1007.
26. Lenz HJ, Van Cutsem E, Khambata-Ford S et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. *J Clin Oncol* 2006; 24: 4914–4921.
27. Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. *Biol Pharm Bull* 2006; 29: 903–906.
28. Nakajima G, Hayashi K, Xi Y et al. Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in Colon Cancer. *Cancer Genomics Proteomics* 2006; 3: 317–324.
29. Weiss GJ, Bemis LT, Nakajima E et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. *Ann Oncol* 2008; 19: 1053–1059.